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Abstract
Background: Depression is one of the most common mental health disorders and severely impacts one’s physical, psychological,
and social functioning. To address access barriers to care, we developed Ascend—a smartphone-delivered, therapist-supported,
8-week intervention based on several evidence-based psychological treatments for depression and anxiety. A previous feasibility
study with 102 adults with elevated depression reported that Ascend is associated with a postintervention reduction in depression
symptoms.
Objective: We aimed to examine whether Ascend is associated with a reduction in symptoms of anxiety, and importantly,
whether reductions in symptoms of depression and anxiety are maintained up to 12-months postintervention.
Methods: We assessed whether the previously reported, end-of-treatment improvements seen in the 102 adults with elevated
symptoms of depression extended up to 12 months posttreatment for depression symptoms (measured by the Patient Health
Questionnaire-9 [PHQ-9]) and up to 6 months posttreatment for anxiety symptoms (added to the intervention later and measured
using the Generalized Anxiety Disorder-7 [GAD-7] scale). We used linear mixed effects models with Tukey contrasts to compare
time points and reported intention-to-treat statistics with a sensitivity analysis.
Results: The intervention was associated with reductions in symptoms of depression that were maintained 12 months after the
program (6.67-point reduction in PHQ-9 score, 95% CI 5.59-7.75; P<.001; Hedges g=1.14, 95% CI 0.78-1.49). A total of 60%
of the participants with PHQ-9 scores above the cutoff for major depression at baseline (PHQ≥10) reported clinically significant
improvement at the 12-month follow-up (at least 50% reduction in PHQ-9 score and postprogram score <10). Participants also
reported reductions in symptoms of anxiety that were maintained for at least 6 months after the program (4.26-point reduction
in GAD-7 score, 95% CI 3.14-5.38; P<.001; Hedges g=0.91, 95% CI 0.54-1.28).
Conclusions: There is limited evidence on whether outcomes associated with smartphone-based interventions for common
mental health problems are maintained posttreatment. Participants who enrolled in Ascend experienced clinically significant
reductions in symptoms of depression and anxiety that were maintained for up to 1 year and 6 months after the intervention,
respectively. Future randomized trials are warranted to test Ascend as a scalable solution to the treatment of depression and
anxiety.
(JMIR Mhealth Uhealth 2019;7(8):e14284)  doi: 10.2196/14284
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Introduction
Depression is a common mental health disorder and one of the
leading causes of disease burden and disability worldwide [1-3].
Individuals with depression have a reduced capacity to work
and function in daily life, causing major economic and societal
costs [4-6]. By 2030, depression is predicted to pose the largest
burden of disease in high-income countries, surpassing heart
disease, dementia, and alcohol-related disorders [1].
Although there are several effective pharmacological [7] and
psychological [8,9] treatments for depression, less than half of
all individuals who require treatment actually receive it [10,11].
Barriers to treatment include financial and time constraints,
long wait periods, a shortage of trained professionals, and fear
of stigmatization [12,13]. When treated with antidepressants,
an estimated 30%-50% of patients do not experience significant
symptom reduction [14], up to 80% of patients report at least
one mild-to-severe side effect [15], and few patients maintain
a state of long-term remission [16]. Estimates suggest that up
to 70% of individuals with depressive disorders have a comorbid
anxiety disorder, which renders treatment even more challenging
[17]. Further, up to 75% of patients referred to in-person
psychotherapy either do not enter treatment or discontinue
treatment prematurely [18,19]. Thus, there is an urgent need for
novel, evidence-based treatments for depression and anxiety to
overcome these barriers.
Recently, digital interventions delivered via smartphone apps
have been developed as a means to address this need [20].
Smartphone ownership has seen rapid worldwide growth [21],
and survey data suggest that smartphone-based interventions
may be preferred over other online formats by health care
consumers [22,23]. Smartphone-based interventions offer several
advantages over traditional treatment modalities including
large-scale accessibility and scalability; low costs; patient
anonymity and privacy; standardized content that is less
dependent on therapist skills; flexible usage at a self-determined
time and pace, which is thought to enhance self-efficacy [24];
monitoring of activity, symptoms, and progression in real time;
provision of personalized feedback, motivational support, and
targeted care; and potential to improve adherence to treatment
[25]. Preliminary evidence suggests that smartphone-based
interventions are a promising means to treat depression and
anxiety, with recent meta-analyses reporting small-to-moderate
reductions in clinical symptoms across 27 studies [26,27].
Despite these promising results, several important questions
regarding the design, efficacy, and implementation of
smartphone-based interventions for common mental health
disorders remain unanswered. First, few authors report on the
outcomes of commercially developed smartphone-based
interventions for depression and anxiety, making it difficult to
evaluate their utility [25,28]. Second, despite being generally
effective for the short-term treatment of symptoms of depression
and anxiety, there is a dearth of evidence regarding how long
the beneficial effects of smartphone-based interventions and
other online interventions are maintained posttreatment [29].
This is important because an estimated 50% or more of patients
with major depression or generalized anxiety disorder will
relapse within 6 to 12 months after the end of an initially
effective treatment [30-32]. Thus, investigation of the long-term
outcomes associated with smartphone-based interventions for
depression and anxiety is an important step toward
understanding their true real-world effectiveness. Lastly, despite
an increased interest in transdiagnostic interventions that target
depression and anxiety concurrently [33], most
smartphone-based interventions for mental health are
disorder-specific, and it remains unknown whether
smartphone-based interventions can address symptoms of
depression and anxiety when they are comorbid.
We recently evaluated the feasibility of the Meru Health Ascend
intervention, a novel, 8-week smartphone-based intervention
for elevated symptoms of depression and anxiety, assisted by
a remote therapist [34]. The intervention was found to be
feasible and was associated with a postintervention reduction
in depression. In this study, we extend these findings by
investigating whether the previously reported postintervention
reductions in depression are maintained at a 1-year follow-up,
whether Ascend is associated with reductions in comorbid
symptoms of anxiety, and whether any postintervention
reductions in symptoms of anxiety are maintained at a 6-month
follow-up. Thus, this study aims to lend important insights into
the real-world, long-term impact of smartphone-based
interventions for the treatment of common mental health
problems. We hypothesized that postintervention reductions in
symptoms of depression would be maintained at the 1-year
follow-up and that Ascend would be associated with reductions
in the symptoms of anxiety, which would persist at the 6-month
follow-up. Lastly, as a secondary objective, we aimed to
examine whether participant demographics or intervention
engagement were predictive of symptom change or attrition at
follow-up.
Methods
Research Design
We used a quasiexperimental research design that included a
single-arm, pre- and postintervention assessment of outcomes.
Symptoms of depression were measured before the intervention
(“baseline”); at the end of the 8-week intervention; and at 1, 3,
6, and 12 months postintervention. Symptoms of anxiety were
measured at baseline; week 4 of the intervention; the end of the
8-week intervention; and 1, 3, and 6 months postintervention.
Participants
This study included adult patients treated at the Meru Health
Online Clinic, a national remote health care provider that
currently operates in the United States and Finland. The clinic
has had a rolling enrolment since March 2017. At the time of
this study, 197 enrollees had passed the 6-month
postintervention outcome window (recruited between March
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2017 and June 2018), and 102 passed the 12-month
postintervention outcome window (recruited between March
and December 2017). Our primary analysis includes the latter
group, although we also report the Patient Health Questionnaire
(PHQ-9) results from the former group with 6-month
postintervention outcomes only. The Ascend intervention was
primarily intended to treat symptoms of depression; however,
many individuals with depression also have comorbid symptoms
of anxiety [17]. Thus, to evaluate whether Ascend is also
associated with reductions in symptoms of anxiety, Generalized
Anxiety Disorder-7 (GAD-7) scale measures were added to the
intervention assessment in December 2017. At the time of this
study, 102 of the original 197 enrollees with 6-month
postintervention PHQ-9 outcomes also had GAD-7 (anxiety)
data (recruited between January and June 2018), while 12-month
postintervention anxiety data were not yet available for any
participants. Note that the 102 participants with 6-month
postintervention GAD-7 data are different from the 102
participants with 12-month postintervention PHQ-9 data.
Participants were recruited via online Facebook advertisements
that sought participants for a smartphone-based intervention for
depression that included self-guided smartphone-delivered
content, private access to a therapist via messaging, and an
anonymous group-chat feature with other participants. Prior to
the intervention, participants were given free access to the app
and trained on how to use the group-chat feature and
communicate with their assigned therapist. Participant
demographics (age, gender, and antidepressant medication
status) were acquired at the start of the intervention via an intake
questionnaire administered online. Since medication status was
introduced in July 2017, these data are absent for the first 33
participants. Outcome measures were administered via the app
for all within-intervention time points (including immediately
postintervention) and via email for all follow-up time points.
For inclusion, participants had to provide informed consent via
the Meru Health app, own a smartphone, have at least mild
symptoms of depression (a score≥5 on the PHQ-9 at baseline),
and acknowledge/demonstrate the ability to commit to a
minimum of 20 minutes of practice per day for 6 days per week
across the 8-week intervention (as judged by both the participant
and their assigned therapist). Exclusion criteria included a
previous suicide attempt, severe active suicidal ideation with a
specific plan, severe self-harm, active substance abuse, and a
history of psychosis. Inclusion/exclusion criteria were assessed
prior to enrolment via phone interviews between study
participants and intervention therapists, as per the standard
treatment procedure at the Meru Health Online Clinic.
Participants were not compensated for their time but could
participate in the intervention for free. All participants provided
informed consent for their anonymized data to be used for
research purposes prior to engaging with the intervention. All
procedures were reviewed by the Pearl Institutional Review
Board, which granted exemption for analyses of previously
collected and deidentified data. All procedures performed were
in accordance with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
An a priori sample size calculation was performed for comparing
patient-reported outcome measures (PHQ-9 and GAD-7 scores)
at baseline and follow-up time points. Using an alpha level of
.05, a power of 0.8, and a medium effect size of 0.5, 33 subjects
were needed. Thus, this study was sufficiently powered to detect
a medium effect, even after accounting for substantial dropout
over the course of the 1-year follow-up period.
Intervention
The Meru Health Ascend intervention has been described in
detail previously [34]. Briefly, the intervention consists of 8
modules delivered sequentially over an 8-week period, which
include content derived from evidence-based practices such as
mindfulness-based stress reduction [35], mindfulness-based
cognitive therapy [36], cognitive-behavioral therapy [37], and
behavioral activation therapy [38]. The content includes text;
video; audio-guided mindfulness meditation exercises;
infographics that illustrate cognitive-behavioral therapy
principles; and journal prompts. Daily content and practices
range from 10 to 30 minutes, except for the first day of each
week, in which a series of introductory videos extend the content
to a maximum of 45 minutes. The Meru Health app can be used
on both Android and iOS and is designed to be platform-agnostic
and thus equivalent across different operating systems.
A licensed therapist (employed by Meru Health) provides
support to participants via messaging (and less frequently, phone
calls), throughout the intervention. As part of this support,
therapists review practice logs using a provider “dashboard”
and electronic medical records (that detail participant
engagement and patient-reported outcomes to date) to monitor
individual participant progress. Therapists aim to spend
approximately 20 minutes (on average) supporting each
participant per week of the intervention (including initiating
contact at least 2-3 times per week), but are at liberty to adjust
the levels of support in accordance with each participant’s
individual progress. In addition, participants are free (and
encouraged) to contact their allocated therapist when they
require additional support. Such two-way interaction is designed
to create a system of support that is structured while being
tailored to each participant’s personal preference and needs.
Further, therapists are instructed to conduct a phone-based
assessment for any participants that show signs of mental
deterioration during or immediately after the intervention. In
case of an emergency, such as severe suicidality, the intervention
includes a written security plan, which all participants are
required to review with their therapist before engaging with the
intervention.
Participants are enrolled in groups of 10-15 individuals that
work through the intervention at the same time and can provide
anonymous support to one another via a discussion board within
the app. Specifically, participants can post anonymous
reflections on practices and lessons to the discussion board, to
which their therapist can respond freely, and to which other
group members can respond with prewritten empathy statements
and emoticons. Free cross-talk between participants is not
allowed.
In Finland, Meru Health is approved by the Finnish National
Supervisory Authority for Welfare and Health (Valvira approval
number V/25535/2017) and is compliant with the European
Union General Data Protection Regulation. In the United States,
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Meru Health is compliant with HIPAA (Health Insurance
Portability and Accountability Act of 1996) legislation. All
protected health information is kept in a HIPAA-compliant
electronic medical record, which is housed in cloud-based
storage systems hosted by a company named Datica [39]. All
data are encrypted in transit, end-to-end, and at rest.
Measures
Patient Health Questionnaire
The PHQ-9 is a 9-item depression scale, derived from the full
PHQ and is one of the most widely used instruments to screen
for the presence and severity of depression in primary care [40].
Participants rate each item on a Likert scale from 0 (not at all)
to 3 (nearly every day), with total scores ranging from 0 to 27.
In general, a score of 10 or above suggests the presence of major
depression, and scores of 5, 10, 15, and 20 are taken as cut-off
points for mild, moderate, moderately severe, and severe
depression, respectively. The PHQ-9 has excellent internal
consistency (Cronbach α of 0.89 in primary care settings) and
excellent test-retest reliability [41]. In their original validation
study, Kroenke and colleagues [40] defined a clinically
significant improvement in depression as a 50% reduction in
the PHQ-9 score combined with a postintervention score of <10
(for participants with baseline scores≥10), and this definition
has been further validated in a comparison study [42]. A similar
yet more liberal definition for clinically significant change was
also proposed by Löwe and colleagues [43] as a PHQ-9 score
reduction of ≥5.
Generalized Anxiety Questionnaire
The GAD-7 is a 7-item scale used extensively in outpatient and
primary care settings to screen for the presence and severity of
an anxiety disorder [44]. Participants rate each item on a Likert
scale from 0 (not at all) to 3 (nearly every day), with total scores
ranging from 0 to 21. In general, a score of 10 or above is
suggestive of the presence of anxiety to the extent that further
evaluation is warranted, and scores of 5, 10, and 15 are taken
as cut-off points for mild, moderate, and severe anxiety,
respectively. The GAD-7 has excellent reliability and internal
consistency (Cronbach α of 0.89) and has been validated in
both the general population and primary care settings [44,45].
A clinically significant improvement in anxiety symptoms has
previously been defined as a GAD-7 score reduction of ≥3 [46].
Statistical Analysis
Measures of Engagement
Descriptive statistics were calculated for participant
demographics and week-by-week engagement metrics. For each
participant, we calculated a measure of intervention engagement,
defined as total days in which >3 minutes of app-based
meditation was completed. We used a threshold of 3 minutes,
as this corresponds to the shortest meditation session available
in the intervention. We used logistic regression to explore
whether baseline characteristics were predictive of the
completion of outcome measures at 6 and 12 months
postintervention. Explanatory variables included age, gender,
country, intervention engagement (as defined above), and
baseline PHQ-9 or GAD-7 scores.
Patient-Reported Outcomes
Outcome measures were analyzed using an intention-to-treat
analysis in which all participants with outcome measures at
baseline were included, regardless of intervention engagement
or attrition. We used linear mixed effects models (LMMs)
implemented through LME4 [47] and Tukey contrasts to
compare between time points (using the “multcomp” package
[48]) in the statistical computing software R [computer software]
(version 3.5.2. Vienna, Austria: R Foundation for Statistical
Computing). LMMs are capable of handling missing data and
are considered superior to other ITT approaches such as the last
observation carried forward [49]. We modeled a single
within-subject factor “time” (as a fixed effect) and a separate
baseline for each participant (random-intercept model). Time
was modeled as a categorical predictor, and we therefore did
not enforce a linear relationship between time and outcome
measures. We also ran the model while controlling for
participant age, gender, country, total intervention engagement
(total active days), and total therapist contact, both with and
without two-way interactions with time, which produced
equivalent results. We report the contrast estimate, 95% CI of
the estimate, and  P value.  P values<.05 were considered
significant. The estimated marginal mean and standard error
for each time point was calculated using the “emmeans” package
in R.
Sensitivity Analysis
Since LMMs rely on data being “missing at random,” an
assumption that is difficult to verify in clinical research, we also
implemented an LMM-based pattern-mixture model (PMM)
for the analysis of PHQ-9 (depression) scores. PMMs are based
on a joint modeling of outcomes and missingness and can
account for data that is “missing not at random” [50]. We
modified the estimated marginal mean (EMM) from the
previously described LMM at the 6- and 12-month time points
based on specific clinical assumptions about participants with
missing data. We identified three patterns of data: (1)
participants with complete outcome data at baseline and
12-month follow-up (n=52); (2) participants who were lost to
follow-up during or immediately postintervention (n=21); and
(3) participants who were lost to follow-up at the 1-, 3-, 6-, or
12-month follow-up time points (n=29). We used the
conservative approach of assuming that participants belonging
to pattern 2 did not benefit from the intervention, and we set
the EMM at 6 and 12 months of follow-up equal to the EMM
at baseline for these participants. For group 3, we estimated the
EMM at the 6- and 12-month follow-ups as being equal to the
EMMs across the first three time points of the intervention
(baseline to week 4). The overall treatment effect at 6 or 12
months of follow-up was then defined as a linear combination
of EMMs for the three different patterns, weighted by the
proportion of participants belonging to each pattern. The
standard error for this estimate was calculated using the delta
method (via the “car” package in R [51]), and a test of the null
hypothesis of no treatment effect was performed using a Wald
statistic. A full description of the LMM-based PMM procedure
is provided in a previous paper [52].
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Effect Size Calculation
For comparisons with previous literature, we calculated effect
size (Hedges g) immediately postintervention and at 6 and 12
months after the intervention as the difference in outcome scores
from baseline divided by the pooled weighted SD (based on
observed outcome scores only). For the PMM, effect size (Cohen
d) was calculated as the estimated reduction in outcome score
(from the LMM-based PMM) divided by the SD of observed
outcome scores at baseline. We also calculated the percentage
of participants who met the definition for clinically significant
improvement in PHQ-9 symptoms postintervention and at the
12-month follow-up, defined as either a 5-point reduction in
PHQ-9 score from baseline or a 50% reduction in PHQ-9 score
combined with a postintervention PHQ-9 score<10 (for
participants with baseline scores ≥10).
Predictors of Outcome Change
Lastly, we performed exploratory multiple regressions to test
whether participant demographics and engagement metrics
predicted outcome change from baseline to 6 and 12 months
postintervention with regard to PHQ-9 scores and from baseline
to 6 months postintervention with regard to GAD-7 scores. In
each case, we excluded participants who did not have an
available change score and modeled the following predictor
variables: age, gender, baseline PHQ-9 or GAD-7 score, total
active days, and total days with therapist contact. Since
antidepressant status was only available for a subset of
participants, we repeated each analysis including and excluding
antidepressant status. In addition, we excluded meditation
minutes from all models, as this was highly correlated with
active days. Predictors associated with a P value<.05 were
considered significant.
Results
Demographics and Participation
Participant demographics for the primary group of participants
with 12-month PHQ-9 data are presented in Table 1. On an
average, participants were 33 years of age, had baseline
symptoms above the cutoff for major depression (mean PHQ-9
score=12.8), and were predominantly female. In addition, 80
participants were based in Finland, while 22 were based in the
United States. Participants based in the United States had
significantly less PHQ-9 symptoms at baseline than those in
Finland (United States: mean 8.33, SD 4.40; Finland: mean
13.9, SD 4.82; t101=4.82; P<.001). Approximately one-third of
the participants were taking antidepressant medication at the
start of the intervention, and 20 participants (19.6%) dropped
out of the intervention, where dropout was defined as less than
4 weeks of active participation during the 8-week intervention
combined with incomplete PHQ-9 (depression) scores
immediately postintervention.
Table 1. Participant demographics and relevant baseline data for the primary study cohort (with Patient Health Questionnaire-9 outcomes available up
to 12-months postintervention).
Did not com-
plete 12-month
outcomes
Did not com-
plete 6-month
outcomes
Did not com-
plete 8-week
outcomes
Completed 12-
month out-
comes
Completed 6-
month out-
comes
Completed 8-
week outcomes
All participantsDemographics and base-
line data
50 (49)58 (56.9)19 (18.6)52 (51)44 (43.1)83 (81.4)102 (100)Total participants, n (%)
34.6 (9.4)32.5 (9.9)31.9 (10.0)31.3 (11.0)33.5 (11.0)33.2 (10.4)32.9 (10.3)Age in years, mean (SD)
Gender, n (%)
13 (26)12 (20.7)4 (21.0)10 (19.2)11 (25)19 (22.9)23 (22.5)Male 
37 (74)46 (79.3)15 (79.0)42 (80.8)33 (75)64 (77.1)79 (77.5)Female 
Antidepressants, n (%)
18 (36)18 (31.0)7 (36.8)7 (13.5)7 (15.9)18 (21.7)25 (24.5)Yes 
22 (44)20 (34.5)7 (36.8)22 (42.3)24 (54.6)37(44.6)44 (43.1)No 
10 (20)20 (34.5)5 (26.3)23 (44.2)13 (29.6)28 (33.7)33 (32.4)Unknown 
Country, n (%)
32 (64.0)44 (75.9)13 (68.0)48 (92.0)36 (81.8)67 (80.7)80 (78.4)Finland 
18 (36.0)14 (24.1)6 (32.0)4 (8.0)8 (18.2)16 (19.3)22 (21.6)Unites States 
11.2 (5.0)12.5 (4.8)11.6 (4.6)14.3 (5.0)13.2 (5.8)13.0 (5.4)12.8 (5.2)Baseline PHQ-9a score,
mean (SD)b
aPHQ-9: Patient Health Questionnaire-9.
bSignificantly associated with the presence of PHQ-9 scores at the 12-month follow-up.
Just over half (51%) of all participants reported a PHQ-9
outcome at 12 months postintervention (Table 1). Logistic
regression revealed that participants with higher depression
scores at baseline (B=–0.11, P=.02) and those who engaged
with the intervention on more days (B=–0.05, P=.009) were
more likely to complete the PHQ-9 at 12 months
postintervention. When including country as a covariate,
participants in the United States were less likely to complete
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PHQ-9 data at 12 months postintervention than participants in
Finland (B=1.89, P=.01), although this may have been driven
by differences in baseline PHQ-9 severity.
We also report participant demographics for a separate group
of patients with anxiety outcomes available at the 6-month
follow-up in Table 2. On an average, baseline GAD-7 scores
suggest that participants had symptoms above the cutoff for
moderate anxiety (mean GAD-7 score=10.7), despite being
recruited on the basis of symptoms of depression. Age, gender,
country, and baseline PHQ-9 symptoms were similar to those
of the primary study cohort presented in Table 1. Intervention
engagement positively predicted completion of the GAD-7 scale
at 6 months postintervention (B=–0.07, P<.001), but baseline
GAD-7 scores did not (P=.99).
Table 2. Participant demographics and relevant baseline data for patients with Generalized Anxiety Disorder-7 outcomes available at 6-months
postintervention.
Did not complete 6-
month outcomes
Did not complete 8-
week outcomes
Completed 6-month
outcomes
Completed 8-week
outcomes
All participantsDemographics and baseline data
57 (55.9)28 (27.5)45 (44.1)74 (72.6)102 (100)Total participants, n (%)
32.2 (10.9)32.1 (10.8)31.0 (12.0)31.5 (11.7)31.7 (11.4)Age in years, mean (SD)
Gender, n (%)
12 (21.1)7 (25.0)4 (8.9)9 (12.2)16 (15.7)Male 
45 (78.9)21 (75.0)41 (91.9)65 (87.8)86 (84.3)Female 
Antidepressants, n (%)
25 (43.9)10 (35.7)22 (48.9)37 (50.0)47 (46.1)Yes 
30 (52.6)17 (60.1)23 (51.1)36 (48.7)53 (52.0)No 
2 (3.5)1 (3.6)0 (0)1 (1.4)2 (1.9)Unknown 
Country, n (%)
12 (21.1)19 (67.9)45 (100)71 (95.9)90 (88.2)Finland 
45 (78.9)9 (32.1)0 (0)3 (4.1)12 (11.8)United States 
10.5 (4.9)9.85 (4.9)10.8 (4.8)11.0 (4.8)10.7 (4.9)Baseline GAD-7a score, mean
(SD)
13.7 (5.4)12.9 (5.5)13.1 (4.4)13.6 (4.7)13.4 (4.9)Baseline PHQ-9b score, mean
(SD)
aGAD-7: Generalized Anxiety Disorder-7.
bPHQ-9: Patient Health Questionnaire-9.
Engagement
Week-by-week intervention engagement rates are summarized
in Table 3. On an average, participants engaged with the
intervention on 31.3 days (SD 13.5, min=3, max=56), which
corresponds to 55.9% of intervention days (where engagement
is defined as >3 minutes of app-based mindfulness meditation
on a given day). Participants completed an average of 9.79 hours
of mindfulness-based exercises (SD 5.01, min=0.79, max=24.7)
and had contact with their therapist on 13.1 days (SD 8.34,
min=0, max=35) or 23.4% of intervention days. In addition, 68
participants (66.7%) completed at least one app-based
meditation practice on each of the 8 weeks of the intervention.
As reported in a previous publication [34], the mean number of
days of intervention engagement (F7,707=42.4, P<.001) and the
mean number of days of therapist contact (F7,707=5.37, P<.001)
decreased from week 1 to week 8 (Table 3). Of the 102
participants, 81.4% completed the PHQ-9 immediately
postintervention, while 43.1% and 51% completed the PHQ-9
at 6 and 12 months postintervention, respectively.
Table 3. Week-by-week intervention engagement across all participants. “Active days” corresponds to >3 minutes of app-based mindfulness practice
on a given day.
WeekMetric
87654321
2.67 (2.20)2.95 (2.21)3.59 (2.34)3.76 (2.19)4.13 (1.95)4.54 (1.95)4.65 (1.89)5.02 (1.81)Active days, mean (SD)
41.5 (39.5)39.0 (39.8)67.7 (55.2)82.6 (60.5)76.1 (47.6)80.6 (40.0)105.9 (52.6)93.9 (39.0)Meditation minutes, mean (SD)
1.42 (1.37)1.43 (1.43)1.46 (1.45)1.47 (1.42)1.75 (1.40)1.65 (1.40)1.90 (1.53)2.02 (1.27)Days with therapist contact,
mean (SD)
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Patient-Reported Outcomes
Depression Symptoms
Participants reported clinically significant improvements in
depression symptoms (PHQ-9 scores) from baseline to
postintervention (5.50-point reduction, 95% CI 4.58-6.42;
P<.001, Hedges g=1.02, 95% CI 0.71-1.32; Figure 1, panel A).
This improvement was maintained at 6 months (6.76-point
reduction, 95% CI 5.61-7.90; P<.001; Hedges g=1.30, 95% CI
0.91-1.68) and 12 months (6.67-point reduction; 95% CI
5.59-7.75; P<.001; Hedges g=1.14, 95% CI 0.78-1.49)
postintervention. The improvement at 6 months remained robust
when including an additional 95 participants (total n=197) with
outcomes available at 6 months postintervention only (6.53-point
reduction, 95% CI 5.73-7.33; P<.001; Hedges g=1.28, 95% CI
1.00-1.55).
When considering participants with PHQ-9 scores≥10 at baseline
(n=83), 48% reported a clinically significant improvement
immediately postintervention, which increased to 60% at the
12-month follow-up (defined as postintervention score<10
combined with ≥50% symptom reduction). When including all
participants and using the more liberal definition of a 5-point
reduction in PHQ-9 symptoms, 56% reported clinically
significant improvements immediately postintervention, which
increased to 77% at the 12-month follow-up.
Figure 1. Estimated marginal means for PHQ-9 (A) and GAD-7 (B) scores across all available timepoints. The dotted line indicates the last week of
the 8-week intervention. Error bars represent standard error of the mean. PHQ-9: Patient Health Questionnaire (9-item version); GAD-7: Generalized
Anxiety Disorder (7-item version).
Sensitivity Analysis
We also estimated PHQ-9 scores at 6 and 12 months
postintervention under the conservative assumption that
participants with missing data did not experience any long-term
benefit from the intervention or benefitted only marginally (see
Methods). This approach revealed more modest yet significant
reductions in PHQ-9 scores relative to baseline at both 6 months
(4.35-point reduction, 95% CI 3.65-5.06; P<.001; Cohen d=0.83,
95% CI 0.43-1.24) and 12 months (4.31-point reduction, 95%
CI 3.63-4.99; P<.001; Cohen d=0.82, 95% CI 0.42-1.23)
postintervention.
Anxiety Symptoms
Participants reported clinically significant improvements in
anxiety (GAD-7 scores) from baseline to postintervention
(3.45-point reduction, 95% CI 2.51-4.38; P<.001; Hedges
g=0.69, 95% CI 0.38-1.00; Figure 1, panel B). This improvement
was maintained at 6 months postintervention (4.26-point
reduction, 95% CI 3.14-5.38; P<.001; Hedge g=0.91, 95% CI
0.54-1.28).
Predictors of Outcome Change
Individuals with higher PHQ-9 symptoms (b=0.54, P<0.001)
or higher GAD-7 symptoms (b=0.63, P<.001) at baseline were
likely to experience larger reductions in depression (at the
12-month follow-up) and anxiety (at the 6-month follow-up),
respectively. However, none of the reported engagement metrics
or participant demographics were predictive of score change
from baseline to 6- and 12-month follow-ups, for either PHQ-9
or GAD-7 (all P>.05).
Discussion
Principal Findings
The Meru Health Ascend intervention is a newly developed,
smartphone-based, therapist-supported intervention for
depression and anxiety, designed to overcome common barriers
to treatment. A recent feasibility study reported that the
intervention is feasible and associated with reduced depression
symptoms immediately after the intervention [34]. This
follow-up study extends these findings by demonstrating that
the intervention is associated with clinically significant
reductions in symptoms of both depression and anxiety and that
these reductions are maintained up to 1 year and 6 months after
intervention completion, respectively.
Understanding whether improvements in symptoms associated
with Ascend are maintained long-term is important, as evidence
suggests that a large proportion of patients are likely to relapse
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following treatment for depression or anxiety [30,32]. Although
relapse rates associated with other smartphone-based
interventions for depression and anxiety are largely unknown,
previous research suggests that the risk of relapse is substantially
lower following psychotherapy than following pharmacotherapy,
where as many as 50%-75% of patients are likely to experience
significant return of symptoms within 12 months of withdrawal
from the latter [53,54]. Our results suggest that, similar to
in-person psychotherapy, Ascend may be associated with
enduring effects that extend for up to 12 months beyond the
end of treatment. However, further work is needed to understand
the long-term effectiveness of Ascend and other
smartphone-based interventions for depression and anxiety
under controlled conditions and relative to conventional
treatment methods.
Our analysis revealed a larger effect size for the reduction in
depression symptoms 12 months postintervention (g=1.14) than
was reported by a recent meta-analysis [26] comparing
smartphone-based interventions for depression to inactive
control groups (g=0.56). However, this study was uncontrolled,
and we therefore caution the reader not to overinterpret this
difference. Indeed, the large effect reported here is consistent
with other within-group (uncontrolled) effect sizes for app- and
online-based depression interventions [55-57]. Further, a recent
meta-analysis reported a similar uncontrolled effect size of
g=1.29 for the reduction in depression symptoms associated
with transdiagnostic, internet-delivered cognitive-behavioral
therapy for depression and anxiety at follow-up [33]. Together,
this suggests that the aforementioned discrepancy may stem
from the lack of a comparison group in our study. We observed
that the reduction in depression symptoms remained significant
when making a conservative assumption that participants with
missing data did not experience any long-term benefit from the
intervention. However, the average reduction in depression
under this assumption was marginally below the threshold for
clinical significance (5-point change in PHQ-9 symptoms).
Similarly, our study revealed a slightly higher effect size for
the reduction in anxiety symptoms immediately after the
intervention (g=0.69) and 6 months postintervention (g=0.91)
than was recently reported in a meta-analysis [27] comparing
smartphone-based interventions for anxiety symptoms to
inactive or waitlist control groups (g=0.45) [27]. This
discrepancy may also be explained by the fact that this study
was uncontrolled, and the effect size reported here may thus be
an overestimate. In addition, the interventions included in the
aforementioned meta-analysis were approximately 2 weeks
shorter (on average) than the current 8-week intervention.
Further, this study recruited participants on the basis of elevated
symptoms of depression (as opposed to anxiety), making it
difficult to make direct comparisons. Interestingly, the slightly
higher effect size reported here is consistent with the results
from online (as opposed to app-based) psychological
interventions for anxiety disorders [58,59] and is, in fact, slightly
lower than the effect size reported by a recent meta-analysis
[33] of transdiagnostic, internet-delivered cognitive-behavioral
therapy for depression and anxiety (uncontrolled pretest to
follow-up, g=1.29).
The finding that Ascend was associated with reductions in
symptoms of anxiety as well as depression is unsurprising, given
that the intervention comprises evidence-based practices that
have previously been shown to be effective at treating both
conditions [60]. In addition, depression and anxiety are highly
comorbid, suggesting the presence of shared underlying
mechanisms that may respond to similar treatment methods
[61]. Indeed, baseline scores suggest that a large proportion of
participants were experiencing anxiety symptoms before the
intervention, despite being recruited on the basis of having
symptoms of depression. However, the magnitude of symptom
reduction associated with Ascend was slightly larger for
depression than for anxiety, likely reflecting the fact that the
intervention was designed to address depression as the primary
condition. Although previous online psychological interventions
have often separated the treatment of depression and anxiety
symptoms, there has been a recent trend toward the development
of transdiagnostic interventions that target mechanisms common
to multiple psychiatric disorders. These results add to a growing
body of evidence highlighting the feasibility of such
interventions [33] and suggest that smartphone apps may have
the potential to address symptoms of depression and anxiety
concurrently.
Two important but largely unanswered questions are who is
likely to benefit the most from app-based psychological
interventions and what factors are predictive of the degree to
which individuals benefit over time. Our previous feasibility
study suggested that a greater volume of app-based practice
predicted the occurrence of fewer depressive symptoms 4 weeks
after completing the Ascend intervention [34]. In this study, the
degree of engagement with Ascend did not impact depression
or anxiety scores at 6 or 12 months postintervention, although
this analysis was likely underpowered due to a large proportion
of missing data at these time points. It is also likely that a portion
of the variance in scores at these time points was driven by
factors not captured by our study. Further research is needed to
understand the factors and components of the intervention that
are predictive of long-term benefits.
Limitations
As with the former feasibility study [34], this study used a
nonrandomized, uncontrolled design, which precludes causal
inferences regarding the intervention and patient-reported
outcome changes. In addition, the effect sizes reported in this
study are likely an overestimate of the true treatment effect
relative to an active control or treatment as usual.
Further, approximately one-third of the participants were taking
antidepressants during (and presumably after) the intervention,
making it difficult to preclude the possibility that the reduction
in depression symptoms was caused or maintained by
antidepressants [62] or by the tendency for a proportion of
depressed patients to naturally recover over a 12-month period
[63] and not by this intervention. Future randomized controlled
trials that compare Ascend to treatment as usual over an
extended period are required to fully address these limitations.
The Meru Health Online Clinic could also consider collecting
information on the antidepressant status at follow-up (and not
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just at baseline) to better tease apart the long-term effects
associated with the current intervention versus antidepressants.
Further, although engagement with the intervention was high,
approximately half of all participants did not complete
questionnaires at 6 and 12 months postintervention. Thus, our
estimates of the percentage of participants that experienced
clinically significant improvements in depression symptoms
was based on the participants with complete data only. Further,
participants with fewer symptoms of depression postintervention
may have been more likely to engage with questionnaires,
biasing estimates of the long-term treatment effect. This was
addressed by using a robust pattern-mixture model approach
and applying the most conservative clinical assumptions about
the treatment effect for participants who dropped out or who
were lost to follow-up. Nevertheless, such assumptions are
inherently unverifiable, and recent guidelines highlight the
importance of minimizing the likelihood of incomplete outcome
data [64].
Although this study suggests that the intervention is associated
with reductions in depression and anxiety symptoms, it does
not address the underlying mechanisms or mediators of outcome
change. Since the intervention encompasses techniques and
practices from multiple approaches (cognitive behavioral
therapy, mindfulness meditation, and behavioral activation
therapy) as well as remote therapist and peer support, it is
difficult to differentiate which components of the intervention
are the most effective. Such information could assist with the
design and optimization of future iterations of Ascend and other
app-based interventions for mental health [65].
Finally, the study included self-selected participants who may
have shown a higher degree of motivation to engage with the
intervention. Further, the majority of participants were female,
and although the study included individuals from both Finland
and the United States, the majority of participants were based
in Finland. Moreover, the Meru Health Clinic does not currently
track patient race and ethnicity, making it difficult to assess the
generalizability of the findings. Together, this suggests that this
study sample may not be representative of the wider population
of individuals with elevated symptoms of depression or anxiety,
and future studies should address this issue by using more robust
recruitment strategies and more representative study samples.
Conclusions
Depression is a serious and growing problem that causes
individual suffering and huge economic and societal costs
worldwide. Many individuals with depression are unable to
access appropriate treatment, with high costs and a lack of
trained professionals being major barriers. Scalable, low-cost,
app-based interventions such as Ascend are designed to
overcome these barriers and may help to significantly reduce
the burden of anxiety and depression. Further research is needed
to investigate the efficacy of Ascend in comparison to control
groups and other established treatments for depression and
anxiety.
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